SSC
ALNY icon

Syverson Strege & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History

Syverson Strege & Co’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-14
Closed -$2.8K – 83
2023
Q1 		$2.8K Buy
+14
New +$2.94K ﹤0.01% 426

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Syverson Strege & Co's ALNY Position: Q2 2023 in Review

Syverson Strege & Co sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2023, closing a stake of 14 shares — an estimated $2.8K sold.

Syverson Strege & Co first reported a position in ALNY in Q1 2023 and held it in 1 quarter. The position peaked at $2.8K in Q1 2023. 476 funds tracked by Wall St. Rank hold ALNY as of Q2 2023.

  • Syverson Strege & Co reported no remaining Alnylam Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Syverson Strege & Co sold 14 Alnylam Pharmaceuticals shares in Q2 2023, an estimated $2.8K.
  • Syverson Strege & Co first reported a position in Alnylam Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Syverson Strege & Co's Alnylam Pharmaceuticals position peaked at $2.8K in Q1 2023.
  • 476 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2023.

Based on Syverson Strege & Co's 13F filing for Q2 2023, filed 4 Aug 2023.